News

US FDA to Issue New Vouchers to Drug Developers to Shorten Review Time
(Reuters) -The U.S. Food and Drug Administration on Tuesday announced that it will issue a new priority review voucher to ...
We Spent a Year Investigating How the FDA Let Risky Drugs Into the U.S. Market
Our investigation exposed a little-known practice inside the FDA that allowed more than 150 drugs or their ingredients into ...
The American Journal of Managed Care37m
FDA Approves Garadacimab-gxii in Hereditary Angioedema
Garadacimab-gxii is the first and only treatment that targets factor XIIa (FXIIa) for the prophylactic prevention of reditary ...
US FDA extends review of KalVista's swelling disorder drug due to heavy workload
By Puyaan Singh (Reuters) -KalVista Pharmaceuticals' said on Friday that the U.S. Food and Drug Administration had extended ...
Kraft Heinz pulling certain artificial dyes from its US products in 2027
Kraft Heinz will be pulling certain artificial dyes from its U.S. products starting in 2027 and will no longer roll out new ...
Capricor Therapeutics' Becker Muscular Dystrophy Drug Gets Orphan Drug Designation in U.S.
Capricor Therapeutics has received an orphan drug designation for its drug aimed at potentially treating Becker Muscular Dystrophy. The biotechnology company said Tuesday that the Food and Drug ...
Kraft Heinz removing all artificial dyes from US products by end of 2027
Kraft Heinz plans to remove all artificial dyes from its U.S. products by 2027 amid the Trump administration's push to remove ...
Futurism on MSN4d
The FDA Is Already Outsourcing Drug and Food Analysis to Error-Plagued AI Chatbot
The FDA plans to "unleash AI" on new drug evaluations in order to "radically increase efficiency in the review process." ...
US FDA puts on hold Rein Therapeutics' lung disease drug trial
Rein Therapeutics has paused patient enrollment and dosing in a mid-stage trial of its lung disease drug in the U.S. after ...
U.S. News & World Report3d
US FDA Extends Review of KalVista's Swelling Disorder Drug Due to Heavy Workload
US FDA Extends Review of KalVista's Swelling Disorder Drug Due to Heavy Workload By Puyaan Singh (Reuters) -KalVista Pharmaceuticals' said on Friday that the U.S. Food and Drug Administration had ...